Table 5.
Subgroup analyses
| Study subgroup (number of studies) | Subgroup | Comparison group | P value for interaction |
|---|---|---|---|
| Odds ratio, (95% CI) | |||
| Statin prescribing (11) | |||
| More than 2 implementation strategies (6) | 2.19 (1.32–3.63) | 2.40 (1.43–4.06) | 0.80 |
| Study published in 2013 or later (5) | 1.97 (1.29–3.01) | 2.84 (1.41–5.74) | 0.36 |
| Conducted in the United States (2) | 4.00 (1.03–15.50) | 1.95 (1.33–2.84) | 0.32 |
| LDL-C (14) | |||
| More than 2 implementation strategies (4) | 1.53 (1.23–1.90) | 1.20 (0.97–1.48) | 0.12 |
| Study published 2013 or later (5) | 1.62 (1.19–2.19) | 1.13 (0.95–1.35) | 0.05 |
| Conducted in the United States (5) | 1.48 (1.12–1.95) | 1.29 (1.03–1.61) | 0.35 |
| Standardized mean difference, (95% CI) | |||
| LDL-C (17) | |||
| More than 2 implementation strategies (6) | − 0.38 (− 0.67; − 0.09) | − 0.07 (− 0.15; − 0.01) | 0.05 |
| Study published in 2013 or later (8) | − 0.12 (− 0.21; v0.02) | − 0.23 (− 0.39; − 0.07) | 0.24 |
| Conducted in the United States (6) | − 0.20 (− 0.36; − 0.04) | − 0.17 (− 0.31; − 0.03) | 0.79 |
Statin adherence was excluded because there were not enough studies to make a comparison